Technology
Health
Biotechnology
Navidea Biopharmaceuticals
$1.389876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.00 (-0.28%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell NAVB and other stocks, options, ETFs, and crypto commission-free!
About
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. Read More The company was founded in 1983 and is headquartered in Dublin, OH.
Employees
19
Headquarters
Dublin, Ohio
Founded
1983
Market Cap
13.91M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
488.14K
High Today
$1.44
Low Today
$1.38
Open Price
$1.44
Volume
2.54K
52 Week High
$2.84
52 Week Low
$0.1005
Collections
Technology
Health
Biotechnology
Therapy
US
North America
News
Yahoo FinanceMay 11
Edited Transcript of NAVB earnings conference call or presentation 8-May-19 9:00pm GMT
Q1 2019 Navidea Biopharmaceuticals Inc Earnings Call DUBLIN May 12, 2019 (Thomson StreetEvents) -- Edited Transcript of Navidea Biopharmaceuticals Inc earnings conference call or presentation Wednesday, May 8, 2019 at 9:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Erika Gibson Navidea Biopharmaceuticals, Inc. - Director of...
Yahoo FinanceMay 8
Navidea Biopharmaceuticals Reports First Quarter 2019 Financial Results
DUBLIN, Ohio--(BUSINESS WIRE)-- Conference Call to be held Wednesday, May 8, 2019 at 5:00 pm ET Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter of 2019. Navidea reported total revenues for the quarter of $136,000. Net loss attributable to common stockholders was $2.4 million. “During the first quarter, Navidea re...
Yahoo FinanceMay 1
Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update
DUBLIN, Ohio--(BUSINESS WIRE)-- Conference Call to be held Wednesday, May 8, 2019 at 5:00 p.m. (EDT) Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, May 8, 2019 at 5:00 p.m. (EDT) to discuss its financial results for the first quarter of 2019. Jed Latkin, Chief Executive Officer, Erika Gibson, Direct...
Price Paid on Robinhood
246% Higher
Right Now
52 Week Low
$0.1005
Average Price Paid
$0.3988
52 Week High
$2.84
Earnings
-$0.24
-$0.16
-$0.08
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 7, After Hours